Lumida
/LAB
⌘K
Standard BioTools Inc

Standard BioTools Inc

LAB
$0.69USD+0.04%+0.00 today

MARKET CAP

270.9M

P/E (TTM)

2.7x

FWD P/E

DAY RANGE

$1 – $1

52W RANGE

$1
$2

AI Summary

Stalk
Sell NowHigh

In this Stage 4 decline, price has broken key support with a Support Failure pattern, and short-term and long-term trends remain down. Despite extreme oversold conditions, there are no signs of stabilization or institutional demand, with declining EMAs acting as resistance. Execution posture is bearish with the medium-term tradable side permitting a sell into rallies. Given unfavorable timing conditions for entering new bearish positions, execution should occur now on any relief bounce into EMAs or resistance areas.

  • 110% upside to $1.35 consensus target from $0.64 current price.
  • Pipeline of innovative bio-tools may expand market share.
  • Negative earnings yield and profitability indicate weak return generation.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$97.9M$106.3M$91.0M$85.3M
YoY %+8.6%-14.4%-6.2%
P / Sales1.0x1.7x6.8x5.7x
EV / Sales1.8x2.7x6.5x6.0x
Gross Profit, Adj.$37.1M$50.5M$44.9M$42.5M
YoY %+36.2%-11.0%-5.2%
Margin %37.8%47.4%49.3%49.9%
EV / Gross Profit4.9x5.6x13.2x12.0x
EBITDA, Adj.$-91.4M$-47.9M$-70.1M$-82.3M
YoY %+47.7%-46.6%-17.4%
Margin %-93.4%-45.0%-77.1%-96.5%
EV / EBITDA-2.0x-5.9x-8.4x-6.2x
EBIT$-116.2M$-76.6M$-127.5M$-110.2M
YoY %+34.1%-66.4%+13.5%
Margin %-118.6%-72.0%-140.1%-129.2%
EV / EBIT-1.6x-3.7x-4.6x-4.6x
Net Income$-190.1M$-74.7M$-184.9M$-74.9M
YoY %+60.7%-147.7%+59.5%
Net Margin-194.1%-70.2%-203.2%-87.8%
EPS (GAAP)-$2.43-$0.94-$0.52-$0.20
YoY %+61.3%+44.7%+61.5%